Ovulation induction in premature ovarian failure: a placebo-controlled randomized trial combining pituitary suppression with gonadotropin stimulation.

What Was Tested

The paper reports a study of Chorionic Gonadotropin and Buserelin, published as a randomized controlled trial.

To determine the effect of pituitary suppression with a GnRH agonist (GnRH-a) on the success of ovulation induction with exogenous gonadotropins in patients with premature ovarian failure (POF).

Who Took Part

PubMed indexes the participants as adults, women only.

Thirty patients with POF, 15 in each group.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Chorionic Gonadotropin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Chorionic Gonadotropin, so expectations could not easily colour the readings.

Some participants received a placebo instead of Chorionic Gonadotropin, giving a reference point.

The data were analyzed with a Fisher exact test.

A tertiary care academic center for Reproductive Endocrinology and Fertility.

What Was Measured

Topics PubMed links to this paper include Buserelin, Chorionic Gonadotropin, Follicle Stimulating Hormone, Ovulation Induction, Pituitary Gland and Primary Ovarian Insufficiency.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Chorionic Gonadotropin and Buserelin.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1995 (Fertility and sterility), a journal based in United States.

More context: the related hCG (human chorionic gonadotropin) library page, all human trials.